Cargando…
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation
BACKGROUND: Fingolimod (FTY720), the first oral treatment for multiple sclerosis (MS), blocks immune cell trafficking and prevents disease relapses by downregulation of sphingosine-1-phosphate receptor. We determined the effect of FTY720 on human T cell activation and effector function. METHODS: T c...
Autores principales: | Mazzola, Maria Antonietta, Raheja, Radhika, Murugaiyan, Gopal, Rajabi, Hasan, Kumar, Deepak, Pertel, Thomas, Regev, Keren, Griffin, Russell, Aly, Lilian, Kivisakk, Pia, Nejad, Parham, Patel, Bonny, Gwanyalla, Nguendab, Hei, Hillary, Glanz, Bonnie, Chitnis, Tanuja, Weiner, Howard L., Gandhi, Roopali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696082/ https://www.ncbi.nlm.nih.gov/pubmed/26714756 http://dx.doi.org/10.1186/s12974-015-0460-z |
Ejemplares similares
-
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015) -
The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016) -
Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011) -
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011) -
The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
por: Stradner, Martin H, et al.
Publicado: (2011)